Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GDC-0994 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Stage I-Dose Escalation | EXPERIMENTAL | - |
| Stage II-Cohort-Expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GDC-0994 | DRUG | Escalating doses of GDC-0994 until maximum tolerated dose is reached |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Histologically or cytologically documented, locally advanced or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable * Evaluable disease or dis...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
GDC-0994 is an investigational small molecule being studied for the treatment of locally advanced or metastatic solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its safety and tolerability in patients with solid tumors.
GDC-0994 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY on the OTC market. The company is conducting clinical trials to evaluate the drug's potential in oncology.
GDC-0994 is in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. The Phase 1 trial has been completed, and the drug is no longer in active clinical trials according to available data.
GDC-0994 has been studied in one clinical trial, identified as NCT01875705. This was a Phase 1 dose-escalation study in patients with locally advanced or metastatic solid tumors. The trial enrolled 40 participants and was conducted in the United States and France. It has been completed.
GDC-0994 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. The drug remains in clinical development and has not been authorized for commercial use by the FDA or any other regulatory agency.